Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 1;43(41):4229-4361.
doi: 10.1093/eurheartj/ehac244.

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

Alexander R Lyon  1 , Teresa López-Fernández  2 , Liam S Couch  1 , Riccardo Asteggiano  3 , Marianne C Aznar  1 , Jutta Bergler-Klein  4 , Giuseppe Boriani  3 , Daniela Cardinale  3 , Raul Cordoba  2 , Bernard Cosyns  5 , David J Cutter  1 , Evandro de Azambuja  5 , Rudolf A de Boer  6 , Susan F Dent  7 , Dimitrios Farmakis  8 , Sofie A Gevaert  5 , Diana A Gorog  1 , Joerg Herrmann  7 , Daniel Lenihan  7 , Javid Moslehi  7 , Brenda Moura  9 , Sonja S Salinger  10 , Richard Stephens  1 , Thomas M Suter  11 , Sebastian Szmit  12 , Juan Tamargo  2 , Paaladinesh Thavendiranathan  13 , Carlo G Tocchetti  3 , Peter van der Meer  6 , Helena J H van der Pal  6 ; ESC Scientific Document Group
Collaborators, Affiliations

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

Alexander R Lyon et al. Eur Heart J. .
No abstract available

Keywords: Amyloid light-chain cardiac amyloidosis; Androgen deprivation therapy; Anthracycline; Arrhythmias; Atrial fibrillation; Biomarkers; Cancer; Cancer survivors; Carcinoid syndrome; Cardiac magnetic resonance; Cardiac tumour; Cardio-oncology; Cardiotoxicity; Chemotherapy; Coronary artery disease; Echocardiography; Fluoropyrimidine; Guidelines; Haematopoietic stem cell transplantation; Heart failure; Hormone therapy; Hypertension; Immunotherapy; Ischaemic heart disease; Myocarditis; Pericardial disease; Proteasome inhibitors; Pulmonary hypertension; QTc prolongation; Radiotherapy; Risk stratification; Strain; Thrombosis; Trastuzumab; Valvular heart disease; Vascular endothelial growth factor inhibitors (VEGFi); Venous thromboembolism.

PubMed Disclaimer

Comment in

Substances